<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57643">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355639</url>
  </required_header>
  <id_info>
    <org_study_id>EXP-1090</org_study_id>
    <nct_id>NCT02355639</nct_id>
  </id_info>
  <brief_title>A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin</brief_title>
  <official_title>A Single-Centre, Explorative, Randomised, Investigator-Blinded, Negative-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess Steroid Induced Skin Atrophy on Healthy Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess steroid induced skin atrophy by sonography.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single Blind (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in skin thickness from baseline to end of treatment</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relation of clinical features (skin transparency and telangiectasia) to the steroid induced skin atrophy after end of treatment</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Skin and Connective Tissue Diseases</condition>
  <arm_group>
    <arm_group_label>Clobetasol propionate 0.05 % ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betamethasone dipropionate 0.064 % ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Petrolatum ointment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol propionate 0.05 % ointment</intervention_name>
    <arm_group_label>Clobetasol propionate 0.05 % ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone dipropionate 0.064 % ointment</intervention_name>
    <arm_group_label>Betamethasone dipropionate 0.064 % ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Petrolatum ointment</intervention_name>
    <arm_group_label>Petrolatum ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers, 25 to 40 years old inclusive.

          2. Healthy skin on volar arms with a hairless area sufficient for measurements

        Exclusion Criteria:

          1. Clinical skin atrophy, telangiectasia or striae on volar arms.

          2. Presence of any skin condition or colouration that would interfere with test sites or
             the response or assessment.

          3. Fitzpatrick skin type IV - VI.

          4. History or current evidence of infection, eczema or other relevant skin disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charit√© - Universitaetsmedizin Berlin, Department of Dermatology and Allergy</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 25, 2015</lastchanged_date>
  <firstreceived_date>January 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
